Take Solutions Hits 2% Upper Circuit on Monday; Launches Rs 5 Crore Innovation Fund Focused on AI and Digital Health

On Monday, Indian markets opened slightly negative, with the Nifty 50 declining 0.57 per cent to 22,581, compared to its previous close of 22,713. Amid this broader weakness, Take Solutions shares were trading at Rs 42.03 at 2:00 PM, up 1.99 per cent from the previous close of Rs 41.21, with the stock locked in the Upper Circuit following the company’s announcement of launching a Rs 5 crore Innovation Fund focused on AI, deep technology, and digital health startups.

Take Solutions Launches Rs 5 Crore Innovation Fund to Back AI, Deep Tech and Digital Health Startups

Take Solutions has launched an Innovation Fund with an initial corpus of Rs 5 crore to invest in high-potential startups across artificial intelligence (AI), deep technology, and digital health, as per its filing dated April 6, 2026.

The fund will focus on early- and growth-stage companies operating at the intersection of AI, scientific innovation, and the health and wellness sector. The initiative reflects the company’s strategic shift towards building scalable, technology-led business models while creating long-term shareholder value.

The investment strategy is centred on four key areas: AI and data intelligence (including AI-driven diagnostics, predictive analytics, and SaaS platforms), longevity and bio-convergence (such as genomics and cellular health), digital health platforms (including remote monitoring and wearable technologies), and technology infrastructure aimed at improving efficiency and scalability in knowledge-led industries.

In addition, recently the company has launched Take.Health, an AI-driven digital health platform designed to convert lifestyle and medical data into personalised, actionable insights, targeting both consumer wellness and enterprise health segments.

About TAKE Solutions

TAKE Solutions Limited is a publicly listed Indian company delivering domain-intensive services in Life Sciences, Software and Information Technology. It provides full-service Clinical, Regulatory and Safety offerings supported by industry-specific technology and analytics, serving global biopharmaceutical, generics and device companies, as well as U.S. federal agencies including the CDC and DoD. The company operates in a single segment, ‘Life Sciences and Support Services’, and is listed on the BSE and NSE.

The company has a market capitalisation of Rs 622 crore. The stock has traded in a 52-week range of Rs 7.40 to Rs 48.86. In terms of returns, it has delivered 403.91 per cent over the past one year, 72.04 per cent over two years, and 163.72 per cent over three years, indicating strong price performance over multiple time periods.

Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.